Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

XL281

Known as: RAF Kinase Inhibitor XL281 
An orally active, small molecule with potential antineoplastic activity. XL281 specifically inhibits RAF kinases, located downstream from RAS in the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
The Ras/Raf/MEK/ERK signaling pathway involves various kinases in which each kinase is associated with one another through… Expand
Is this relevant?
2015
2015
BACKGROUND The use of BRAF inhibitors may lead to the development of cutaneous toxicities such as rashes, photosensitivity… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2014
2014
SummaryBackground XL281 is a potent and selective inhibitor of wild-type and mutant RAF kinases with anti-tumor activity in… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Review
2013
Review
2013
The B-Raf protein is a key signaling molecule in the mitogen activated protein kinase (MAPK) signaling pathway and has been… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
2010
2010
8592 Background: Tumor regressions have been observed in a significant proportion of advanced melanoma patients treated with… Expand
Is this relevant?
2010
2010
  • Douglas W. Ball
  • The Journal of clinical endocrinology and…
  • 2010
  • Corpus ID: 744097
Salerno et al. (1) in this issue of the Journal present the first preclinical thyroid cancer studies to use a promising category… Expand
Is this relevant?
Review
2010
Review
2010
Kinases have become one of the most important families of drug targets for many diseases and for cancer in particular (Zhang et… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
3513 Background: XL281 is a potent and selective inhibitor of wild type and mutant RAF kinases showing anti-tumor activity in… Expand
Is this relevant?
2009
2009
AVos Life sciences has analysed the revenue contribution of organically developed, licensed or co-developed, acquired and joint… Expand
  • figure 1
Is this relevant?